[go: up one dir, main page]

MXPA02010231A - Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. - Google Patents

Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Info

Publication number
MXPA02010231A
MXPA02010231A MXPA02010231A MXPA02010231A MXPA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A
Authority
MX
Mexico
Prior art keywords
treating
disease
neurodegenerative diseases
treatment
amino acid
Prior art date
Application number
MXPA02010231A
Other languages
English (en)
Inventor
Huangshu Lei
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA02010231A publication Critical patent/MXPA02010231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se relaciona a inhibidores BCAT y el uso de los mismos para tratar o prevenir perdida neuronal asociada con apoplejia, isquemia, trauma en e l SNC, hipoglicemia y cirugia, asi como para tratar enfermedades neurodegenerativas incluyendo enfermedad de Alzheimer, esclerosis lateral amiotrofica, enfermedad de Huntington y sindrome de Down, para tratar o prevenir las consecuencias adversas de la sobreestimulacion de los aminoacidos excitadores, tratar ansiedad, psicosis, convulsiones, perdida de audicion inducida por antibioticos aminoglicosidos, migrana, dolor cronico, dolor neuropatico, enfermedad de Parkinson, retinopatia diabetica, glaucoma, retinitis por CMV, incontinencia urinaria, tolerancia y retiro de opioide exogeno y anestesia inducida, asi como por cognicion incrementada.
MXPA02010231A 2001-11-27 2002-10-16 Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. MXPA02010231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33363601P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
MXPA02010231A true MXPA02010231A (es) 2004-12-13

Family

ID=23303625

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010231A MXPA02010231A (es) 2001-11-27 2002-10-16 Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Country Status (8)

Country Link
US (2) US6809119B2 (es)
EP (1) EP1314723A1 (es)
JP (1) JP2003206273A (es)
AU (1) AU2002365311A1 (es)
BR (1) BR0204863A (es)
CA (1) CA2412466A1 (es)
MX (1) MXPA02010231A (es)
WO (1) WO2003045902A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MX2007012688A (es) * 2005-04-15 2008-03-14 Synta Pharmaceuticals Corp Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.
US8609720B2 (en) 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US7939564B2 (en) * 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US8093425B2 (en) * 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
KR101892574B1 (ko) * 2011-01-21 2018-08-28 썬 파마 어드밴스트 리서치 컴패니 리미티드 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제
EP2481801A1 (en) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
WO2014049471A1 (en) * 2012-09-29 2014-04-03 Mahesh Kandula Compositions and methods for the treatment of ventricular arrhythmias and cardiovascular diseases
CN104649944B (zh) * 2015-02-13 2016-08-31 佛山市赛维斯医药科技有限公司 一类甲氧苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104610105B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 烷基取代的苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104649937B (zh) * 2015-02-13 2016-04-13 佛山市赛维斯医药科技有限公司 苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104610103B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 含苯磺酰肼和卤代苯结构gpr119激动剂、制备方法及其用途
CN104649938B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 硝基苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104592066B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 一类苯磺酰肼化合物、制备方法及其用途
CN104592065B (zh) * 2015-02-13 2016-04-06 佛山市赛维斯医药科技有限公司 卤代苯磺酰肼类gpr119激动剂、制备方法及其用途
CN104610104B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含苯磺酰肼和硝基苯结构gpr119激动剂及其用途
CN104628612B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一类腈基苯磺酰肼类gpr119激动剂、制备方法及其用途
WO2021221444A1 (ko) * 2020-04-27 2021-11-04 주식회사 오토텍바이오 Ubr 박스 도메인 리간드로의 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025926A1 (fr) * 1995-02-21 1996-08-29 Nippon Suisan Kaisha, Ltd. Agoniste de recepteur d'acide glutamique
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU784553B2 (en) * 1999-12-08 2006-05-04 Penn State Research Foundation, The Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
WO2002024672A2 (en) * 2000-09-19 2002-03-28 Warner-Lambert Company Llc Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
AU2002225767A1 (en) * 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
JP2003206273A (ja) 2003-07-22
EP1314723A1 (en) 2003-05-28
WO2003045902A1 (en) 2003-06-05
US6809119B2 (en) 2004-10-26
US20030149110A1 (en) 2003-08-07
AU2002365311A1 (en) 2003-06-10
BR0204863A (pt) 2004-06-15
CA2412466A1 (en) 2003-05-27
US20050014841A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA02010231A (es) Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
AU4327101A (en) Aminoadamantane derivatives as therapeutic agents
IL168365A (en) Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis
ZA97991B (en) Novel cyclic amino acids as pharmaceutical agents.
IL125544A0 (en) Novel substituted cyclic amino acids as pharmaceutical agents
ZA972199B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
MXPA03001277A (es) Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas.
EP1021418A4 (en) SUBSTITUTED 2,3-BENZODIAZEPINE-4-ONE AND THEIR USE
NZ276892A (en) Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
EP1983000A3 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
TW200733976A (en) Method for the treatment of cognitive dysfunction
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
MXPA02010430A (es) Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
HUT64841A (en) Process and composition for treating eyes
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
PH12021552681A1 (en) Therapeutic drug for dyskinesia
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
WO2023107630A3 (en) Amino alcohol compounds and uses thereof
WO2024238655A3 (en) Delivery vehicle for targeted delivery to cardiomyocytes
WO2008027345A3 (en) COMBINED γ-SECRETASE INHIBITOR AND PHENOTHIAZINE DERIVATIVE TREATMENT OF NEURODEGENERATIVE DISEASES